JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
about
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedGenetics of myeloproliferative neoplasmsNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroEffects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling.WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms.Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Budd-Chiari syndrome following laparoscopic cholecystectomy.IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathologyMyelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.Low frequency of c-MPL gene mutations in Iranian patients with Philadelphia-negative myeloproliferative disorders.TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemiaGenetic-pathologic characterization of myeloproliferative neoplasms.The use of structural biology in Janus kinase targeted drug discovery.Generation of induced pluripotent stem cells from human blood.Therapeutic potential of JAK2 inhibitors.PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.Janus kinase 2 inhibitors in myeloproliferative disorders.Molecular genetic evaluation of myeloproliferative neoplasms.CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.Is it Primary Myelofibrosis or Chronic Lymphocytic Leukemia Related Secondary Myelofibrosis?Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia.Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms.An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.Targeting the epigenome for treatment of cancer.
P2860
Q26738514-22896220-E0F9-4BA4-8B4F-17C08706F723Q26823651-8371E415-29E5-4413-AC8D-B78BDF6D8F28Q27687464-B51FCD6B-B8AA-4700-B0E4-55DA6116BD23Q30315531-4CE00D82-6FA7-48A4-B6E0-67D8CF9E6C34Q30406240-047B267C-1476-4472-9B0B-BCD166692D89Q33581974-DDB0F42C-5723-4E29-AFF5-D22DCFA97E20Q33751024-CE9DB29D-53D5-44E4-8B46-8B403F178FF7Q33753094-DBCFA9EB-6D1B-4D52-8280-4C12DD6C46F8Q34438858-ED207EB1-503F-4089-AD2C-9BCBA49AC72AQ34562170-2D36D37B-6395-4E52-834A-FC9850B2155CQ34611232-3C0837C6-243F-4001-A452-F405528F82C2Q35386991-2FA6BEE3-090D-4E60-B000-78DD17BF7ACCQ35470697-E7DCDD8A-4ED5-4778-90E0-1EA23B533F5EQ35608167-54BE0824-668D-48F4-93A3-0DABB1C72F13Q36153557-06603901-B5B6-4BEC-BCD4-693581289BEAQ36618587-EA34B88F-8AD1-4DF0-B137-205DA16FB5F1Q36754808-BE148234-3865-4770-9016-95A693FC87B5Q37151437-790C71DC-AF16-4F69-AEAF-CF491CF22890Q37206115-258DBD73-05F8-4E1E-B50B-34801231042DQ37209041-9D17B7DC-9953-4229-A4D2-5764EF0DC742Q37653313-A1BEAD45-A804-4D2D-B0CB-235762DFBED8Q37810947-138E878F-A662-4BF5-B502-EFB6A8210BE0Q37815509-82A8D15C-DFE0-4230-862C-D84E1D73D9A5Q38481945-DDB28FC9-EC4A-4851-BC75-21C1F58B23C3Q39399799-23286712-DD8E-473C-9F10-FC9BE5753C8DQ39482201-42740397-1BA7-4A7C-AA7C-9EF751645412Q41379688-23DD9583-3EB4-4289-B790-4993C232EE48Q41555800-77DDFC51-1610-4593-BBE4-F68DBE7ED24FQ42134799-F51E4621-43E0-4E57-8C2D-D11E197564B9Q42946931-3097E10D-B5B9-403F-A3D8-795813EE85CBQ43122604-D5983FD4-8870-4903-86F2-652A7209461CQ43986169-03B6FA1F-7CC9-4E74-B7DB-981B7F551F9AQ46886345-5836540F-0596-4393-A97A-6DA9E84B9EF8Q47267750-A376C739-9575-4722-8249-74E7606AD8BEQ47815810-260F54C1-0D50-4AB7-9142-7ED9A56B5F20Q48144174-DED174C1-A8A2-4A60-93C7-EB01459E13B3Q48302310-8B8F7277-2117-46C3-A3F2-3349659FD441Q51505022-B1E12876-7D96-4A99-A0A5-9DD34DDD3F49Q53185401-7A1B58A6-A3C2-4FF9-BD36-32F8B1B7E2FAQ53201323-800E0446-8480-4294-B404-5351ACA3F4E8
P2860
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
@en
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
@nl
type
label
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
@en
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
@nl
prefLabel
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
@en
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
@nl
P2860
P356
P1433
P1476
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
@en
P2093
O Kilpivaara
R L Levine
P2860
P2888
P304
P356
10.1038/LEU.2008.229
P577
2008-08-28T00:00:00Z